NOVOCART 3D
Biological
Aesculap Biologics, LLC
Total Payments
$9.0M
Transactions
2,000
Doctors
122
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $559,554 | 92 | 9 |
| 2023 | $1.2M | 174 | 18 |
| 2022 | $1.2M | 204 | 35 |
| 2021 | $1.7M | 332 | 38 |
| 2020 | $1.0M | 320 | 27 |
| 2019 | $1.4M | 449 | 58 |
| 2018 | $1.3M | 264 | 25 |
| 2017 | $611,858 | 165 | 25 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.8M | 1,412 | 97.9% |
| Consulting Fee | $70,928 | 35 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,107 | 12 | 0.5% |
| Food and Beverage | $33,693 | 430 | 0.4% |
| Travel and Lodging | $30,383 | 109 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $10,061 | 2 | 0.1% |
Payments by Type
Research
$8.8M
1,412 transactions
General
$190,171
588 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | Aesculap Biologics, LLC | $5.4M | 5 |
| NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE N3D | Aesculap Biologics, LLC | $2.4M | 3 |
| NOVOCART 3D for the Treatment of Articular Cartiage of the Knee N3D | Aesculap Biologics, LLC | $412,925 | 1 |
| SAFETY AND EFFICACY OF NOVOCART 3D IN THE TREATMENT OF ARTICULAR CARTILAGE DEFECTS FOLLOWING FAILURE ON MICROFRACTURE | Aesculap Biologics, LLC | $377,372 | 2 |
| NOVOCART 3D for the Treatment of Articular Cartilage of the Knee N3D | Aesculap Biologics, LLC | $169,885 | 0 |
| NOVOCART 3D for the Treatment of Articular Cartilage of the Knee (N3D) | Aesculap Biologics, LLC | $11,125 | 3 |
Top Doctors Receiving Payments for NOVOCART 3D
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $8.3M | 1,356 |
| , MD | Orthopaedic Surgery | Logan, UT | $309,645 | 99 |
| , M.D | Specialist | La Mesa, CA | $186,316 | 27 |
| Michael Bauer | Blood Banking & Transfusion Medicine | Castle Rock, CO | $37,500 | 25 |
| , MD | Orthopaedic Surgery | Philadelphia, PA | $33,360 | 44 |
| , MD | Orthopaedic Surgery | San Antonio, TX | $25,774 | 13 |
| , MD | Sports Medicine | Millburn, NJ | $20,700 | 4 |
| , M.D | Sports Medicine | Chicago, IL | $14,555 | 43 |
| , MD | Orthopaedic Surgery | Greenwood, IN | $10,071 | 10 |
| , MD | Orthopaedic Surgery | Lexington, KY | $6,587 | 6 |
| , MD | Orthopaedic Surgery | New York, NY | $3,706 | 35 |
| , MD | Specialist | Van Nuys, CA | $2,737 | 12 |
| , MD | Orthopaedic Surgery | Chestnut Hill, MA | $1,977 | 5 |
| , MD | Sports Medicine | New Orleans, LA | $1,878 | 12 |
| Mohammed Khan | Orthopaedic Surgery | Ann Arbor, MI | $1,693 | 11 |
| , MD | Orthopaedic Surgery | Columbia, MO | $1,680 | 17 |
| , M.D | Sports Medicine | Aurora, CO | $1,549 | 16 |
| , M.D | Orthopaedic Surgery | Minneapolis, MN | $1,260 | 6 |
| , MD | Orthopaedic Surgery | Grants Pass, OR | $1,192 | 4 |
| Devin Lemmex | — | Durham, NC | $1,175 | 4 |
| , M.D | Orthopaedic Surgery | Lawrenceville, GA | $1,162 | 6 |
| , M.D | Surgery | Boise, ID | $1,083 | 6 |
| , MD | Orthopaedic Surgery | Allentown, PA | $986.74 | 7 |
| , M.D | Orthopaedic Surgery | Columbia, MO | $939.65 | 4 |
| , MD | Orthopaedic Surgery | Chestnut Hill, MA | $910.04 | 11 |
Ad
Manufacturing Companies
- Aesculap Biologics, LLC $9.0M
Product Information
- Type Biological
- Total Payments $9.0M
- Total Doctors 122
- Transactions 2,000
About NOVOCART 3D
NOVOCART 3D is a biological associated with $9.0M in payments to 122 healthcare providers, recorded across 2,000 transactions in the CMS Open Payments database. The primary manufacturer is Aesculap Biologics, LLC.
Payment data is available from 2017 to 2024. In 2024, $559,554 was paid across 92 transactions to 9 doctors.
The most common payment nature for NOVOCART 3D is "Unspecified" ($8.8M, 97.9% of total).
NOVOCART 3D is associated with 6 research studies, including "NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D)" ($5.4M).